Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616694 · ClinicalTrials.gov registry record · Phase 4
Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 248
- Enrollment target
NCT00616694: Completed Phase 4 study, sponsored by Sanofi.
NCT00616694 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 248 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00616694, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 248 participants
- Enrollment target
Study Summary
To evaluate the effect of subject knowledge of their disease status on persistence in subjects receiving Actonel 5 mg daily over a 12-month period for the prevention and treatment of GIO.
Interventions
- DRUG Actonel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2002-07 |
| Est. Completion | 2004-12 |
| Phase | Phase 4 |
What the finished NCT00616694 record still lists
NCT00616694 is an interventional study that assigns participants to a tested intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 1 intervention - of which Actonel is the first listed.
NCT00616694 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00616694 about?
NCT00616694 is a clinical study titled "Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy". To evaluate the effect of subject knowledge of their disease status on persistence in subjects receiving Actonel 5 mg daily over a 12-month period for the prevention and treatment of GIO.
What is the current status of trial NCT00616694?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 248 participants. The study started on 2002-07. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00616694?
The interventions under investigation include: Actonel (DRUG).
Who is sponsoring clinical trial NCT00616694?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00616694's enrollment target sits among peer trials
248 353rd of 2000 higher than 1,646 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577911 · 248 participants
How is Social Connection Represented in the Brain?
- NCT04777994 · 248 participants · Phase 1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NCT04792489 · 248 participants · Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
- NCT04830137 · 248 participants · Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia